Factors affecting self-reported bleeding acceptance in acute ischemic stroke survivors on various types of antithrombotic therapy

Stroke causes long-term serious disability with global prevalence of 101 million people in 2019.1 Antithrombotic therapy is recommended for stroke secondary prevention depending on the acute ischemic stroke (AIS) subtype.2 One of the major causes of non-cardioembolic AIS is intracranial atherosclerosis, which requires single antiplatelet therapy (SAPT), mostly with aspirin.3,4 Dual antiplatelet therapy (DAPT) may reduce the risk of non-cardioembolic stroke by 29% in AIS attributable to severe intracranial stenosis when used for a limited period of time.
Source: Journal of Stroke and Cerebrovascular Diseases - Category: Neurology Authors: Source Type: research